The director of this ASX company just made another sizeable share purchase

More insider buying action has failed to prop up the Polynovo share price.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points
  • Polynovo shares backtrack 4.6% to $1.14 
  • Polynovo chair, David Williams topped up his holdings through an on-market trade of close to 80,000 shares 
  • Since the beginning of May, Mr Williams has spent around $4.65 million on Polynovo shares 

In a sea of red across the ASX today, the Polynovo Ltd (ASX: PNV) share price is faring no better.

During early afternoon trade, the medical device company's shares are swapping hands at $1.14, down 4.6%.

This comes despite Polynovo announcing another sizeable share purchase from one of its directors.

For context, the All Ordinaries Index (ASX: XAO) is 0.95% in the red to 7,391.9 points.

A cool young man walking in a laneway holding a takeaway coffee in one hand and his phone in the other reacts with surprise as he reads the latest news on his mobile phone

Image source: Getty Images

Polynovo insider buying action continues

Following the recent market slump, the company's chair, David Williams has decided to take advantage of the Polynovo share price weakness.

According to its release, Polynovo advised that Mr Williams has bought 79,557 shares at a price of $1.1849 apiece. This was conducted via an on-market trade by Mr Williams' subsidiary, Lawn Views Pty Ltd.

The transaction equates to a value of more than $94,000.

Following the latest purchase, this means that Mr Williams now has over 23.24 million fully paid ordinary Polynovo shares across all holdings.

The latest buy-in reflects that a number of insiders, particularly Mr Williams believe Polynovo shares are trading at bargain levels.

It is worth noting that at the beginning of May, Polynovo shares touched a 52-week low of 83.5 cents.

It's also worth noting that Mr Williams has made a number of purchases since the beginning of May 2022. In fact, he has spent around $4.65 million over that time.

Polynovo share price summary

Despite this month's 19% gain, Polynovo shares have fallen by 55% in the past 12 months.

Year to date, its shares are down roughly 25%.

Based on today's price, Polynovo presides a market capitalisation of approximately $817.18 million.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended POLYNOVO FPO. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A group of people in a corporate setting do a collective high five.
Healthcare Shares

Up 1,173% in a year, what do 4DMedical shares have over other healthcare stocks?

Expert explains why 4DMedical is somewhat sheltered from today's sector headwinds.

Read more »

A couple sits on the bed in their hotel room wearing white robes, both have seen the bad news on their phones.
Earnings Results

What's going on with ResMed shares today?

The sleep disorder treatment company has released its third-quarter update this morning.

Read more »

A young man sits at his desk working on his laptop with a big smile on his face.
Healthcare Shares

Resmed reports double-digit revenue and profit increases in Q3 FY26

Resmed posted double-digit revenue and profit growth in Q3 FY26, with management confident about continued momentum.

Read more »

a woman puts her fingers in her ears with a pained expression on her face with her eyes closed as though trying to block hearing bad news or an unpleasant loud noise.
Healthcare Shares

Cochlear shares crashed in April, but is a comeback looming?

This ASX 200 healthcare stock is caught between short-term pain and long-term potential.

Read more »

A medical researcher rests his forehead on his fist with a dejected look on his face while sitting behind a scientific microscope with another researcher's hand on his shoulder, as if giving comfort.
Healthcare Shares

What's making healthcare the worst sector on the ASX 200, down 39% in a year?

An expert outlines the key headwinds weighing on the industry and share prices today.

Read more »

woman testing substance in laboratory dish, csl share price
Healthcare Shares

Good news, falling shares: What's dragging this ASX stock lower?

In biotech, strong updates don't always push the share price higher.

Read more »

A graphic showing a businessman running up a white upwards rising arrow symbolising the soaring Magellan share price today
Healthcare Shares

Guess which ASX All Ords healthcare share is rocketing 18% in Thursday's sinking market

Investors are piling into the ASX healthcare share on Thursday. But why?

Read more »

A woman sits at her computer with her chin resting on her hand as she contemplates her next potential investment.
Healthcare Shares

Mesoblast shares: Cash burn falls and Ryoncil® sales climb

Mesoblast reports higher Ryoncil® sales, improved cash management, and research milestones for the March 2026 quarter.

Read more »